ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

LXRX vs OLMA // EV/EBITDA & P/E VALUATION

Lexicon Pharmaceuticals Inc. (NASDAQ) VS. Olema Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: LXRX 4 — OLMA 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LXRX VS. OLMA) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC LXRX OLMA SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 96.00% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -31.50% -32.80% +1.30 LXRX /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield -10.30% -22.88% +12.58 LXRX /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin -60.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) 180.00% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 5/9 2/9 +3.00 LXRX /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 29.1 39.9 -10.86 OLMA /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $658.5M $641.4M $17.2M LXRX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR LXRX REV OLMA REV LXRX GROSS % OLMA GROSS % LXRX FCF OLMA FCF
FY 2025 $49.8M $0 98.0% — -$67.9M -$146.7M
FY 2024 $6.0M $0 89.7% — -$179.8M -$104.5M
FY 2023 $1.1M $0 — — -$161.9M -$83.7M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LXRX // BETA —
OLMA // BETA —